^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IDP-023

i
Other names: IDP-023, G-NK cell therapy, allogeneic FcεRIγ-deficient NK cells, G-NK cells
Company:
Indapta Therap
Drug class:
NK cell stimulant
Related drugs:
17d
New P1 trial
|
IL2 (Interleukin 2)
|
cyclophosphamide • fludarabine IV • mesna • IDP-023 • Proleukin (aldesleukin) • Ocrevus (ocrelizumab)
1year
New P1/2 trial • Combination therapy • Metastases
|
Rituxan (rituximab) • cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • mesna • IDP-023 • Proleukin (aldesleukin)
over1year
FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients. (ASCO 2023)
G-NK cells are associated with improved OS and PFS in trastuzumab-treated patients from both clinical trials and real-world datasets, suggesting their presence may serve as a predictive marker for treatment efficacy. Adoptive transfer of g-NK cells is being explored to augment the efficacy of therapeutic monoclonal antibodies. >Datasets used in analyses: CALGB 40601 trial, C1-2 and C5; Finland Herceptin trial, C3-4 and C6-7; Molecular Taxonomy of Breast Cancer International Consortium, C8; Tempus Labs, RWD1-2.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Tempus xT Assay
|
Herceptin (trastuzumab) • IDP-023